[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Affiliated Hospital Of Guizhou Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":220},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,68,96,123,143,171,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100642972","safety-and-efficacy-of-middle-meningeal-artery-embolization-for-the-treatment-of-migraine-100642972",false,"NCT07633067","Safety and Efficacy of Middle Meningeal Artery Embolization for the Treatment of Migraine.","Safety and Efficacy of Middle Meningeal Artery Embolization for the Treatment of Migraine: A Multicenter, Prospective, Double-blind, Multigroup, Randomized Controlled Trial.","FAST-EM-2","Inclusion Criteria:\n\n1. Age 18\\~80 years old (inclusive), regardless of gender.\n2. Voluntary written informed consent.\n3. Migraine diagnosed by neurologists\u002Fpain specialists according to the current International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria for migraine with or without aura.\n4. Migraine attack frequency of no less than 4 days per month within one month prior to enrollment.\n5. History of pharmacotherapy for migraine prophylaxis or treatment for at least 6 months.\n\nExclusion Criteria:\n\n1. Findings on cerebral angiography indicating secondary headache due to intracranial vascular disorders, including dural arteriovenous fistula, arteriovenous malformation, venous malformation, or other relevant cerebrovascular lesions; Moyamoya disease; or high-risk vascular anatomical variants unsuitable for safe vascular access or contraindicating MMA embolization.\n2. Complicated with cervical spondylosis and secondary headache of otogenic, rhinogenic, odontogenic origin; patients with a history of trigeminal autonomic cephalalgias; headache with other definite etiologies or secondary headache;\n3. Imaging diagnosis shows acute or chronic subdural hematoma, other acute intracranial lesions and other space-occupying lesions;\n4. Patients planning to undergo surgery within 90 days;\n5. Patients with a life expectancy of less than 12 months;\n6. Patients with a definite history of contrast media allergy;\n7. Patients with a history of opioid addiction;\n8. Breastfeeding or pregnant women, or patients with fertility plans within half a year;\n9. Subjects who participated in other clinical trials of drugs or medical devices before enrollment and did not reach the time limit of the primary study endpoint;\n10. Unable to understand headache-related assessment data such as headache diaries and requiring assistance from others to complete them;\n11. Patients with poor compliance judged by the investigator and unable to complete the study as required;\n12. Patients with a definite history of allergy to embolization materials such as nitinol alloy and\u002For cobalt-based alloy, platinum-tungsten alloy, etc.;\n13. Subjects with other comorbidities that restrict their participation in the study, prevent compliance with follow-up, or affect the scientific integrity of the study;\n14. Other conditions in which the investigator considers the patient inappropriate to participate in this study.","ALL","18 Years","80 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is a multicenter, prospective, double-blind, multi-arm, randomized controlled trial that investigates whether middle meningeal artery embolization is superior to current standard pharmacotherapy for migraine. The main objectives of the study are to explore whether middle meningeal artery embolization can reduce migraine patients' dependence on migraine medications and to assess the safety of middle meningeal artery embolization with coils.",[28],"Migraine",[28,30,31],"Middle meningeal artery","Embolization","NOT_YET_RECRUITING","2026-06-05",{"date":35,"type":36},"2026-06-08","ACTUAL",{"date":38,"type":22},"2026-06-15",{"date":40,"type":22},"2028-12-31",{"name":42,"class":43},"The Affiliated Hospital Of Guizhou Medical University","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100481402","prognostic-analysis-of-different-treatment-options-for-cerebral-hemorrhage-100481402","NCT05548530","Prognostic Analysis of Different Treatment Options for Cerebral Hemorrhage","Analysis of Related Factors of Hematoma Morphology in Patients With Cerebral Hemorrhage and Prognosis Analysis of Different Regimens for Cerebral Hemorrhage","Inclusion Criteria:\n\n1. Age 18-80 years old;\n2. Intracerebral hemorrhage was diagnosed by head CT examination;\n\nExclusion Criteria:\n\n1. Multiple intracranial hemorrhage;\n2. Intracranial hemorrhage caused by intracranial tumor, aneurysm, trauma, infarction or other lesions;\n3. Coagulation disorders or a history of taking anticoagulants;\n4. Infectious meningitis, systemic infection;\n5. History of severe stroke, heart, kidney, liver and lung dysfunction in the past;\n6. Severe brain herniation (mydriasis, respiratory and circulatory failure);\n7. Incomplete or missing basic data or follow-up information in the hospital.",true,{"count":53,"type":22},1000,"OBSERVATIONAL","To analyze the influence of early hematoma morphology on hematoma expansion, optimize the treatment plan for cerebral hemorrhage, and guide the treatment of patients with cerebral hemorrhage in combination with clinical practice.",[57],"Brain Hemorrhage","RECRUITING","2026-03-16",{"date":61,"type":36},"2026-03-18",{"date":63,"type":36},"2014-01-01",{"date":65,"type":22},"2028-01-31",{"name":42,"class":43},1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100607052","study-on-the-effect-of-ultra-early-autologous-cranioplasty-on-neurological-function-recovery-100607052","NCT07183540","Study on the Effect of Ultra-early Autologous Cranioplasty on Neurological Function Recovery","Study on the Effect of Ultra-early Autologous Cranioplasty on Neurological Function Recovery: a Multicenter, Prospective, Open-label, Endpoint-blinded, Randomized Controlled Study","FAST-ECP","Inclusion Criteria:\n\n1. Decompressive craniectomy due to craniocerebral trauma, cerebral ischemia and cerebral hemorrhage.\n2. Age 18 - 80 years.\n3. The first time for cranial repair.\n4. unilateral skull defect.\n5. Compliant with recommended decompressive bone flap surgery and autogenous decompressive bone flap after bone flap collection\n6. signed the informed consent.\n\nExclusion Criteria:\n\n1. Poor healing of skin flap (active infection, non-healing, necrosis, sinus, thin or poor blood supply, etc.).\n2. Fracture of bone flap ≥2 pieces, partial open fracture\n3. Intracranial infection before operation.\n4. Severe bone metabolic diseases.\n5. Long-term use of immunosuppressants.\n6. Pregnant or lactating women.\n7. Coagulation disorders.\n8. Severe cardiopulmonary insufficiency.\n9. It is estimated that the CP process cannot be completed within 6 weeks after the bone plate decompression surgery.\n10. Skull defect size less than 25cm².\n11. Life expectancy less than 1 year.\n12. mRS greater than 1 before primary disease.\n13. Diabetic patients.\n14. Patients who are unable to cooperate with follow-up assessment (e.g. mental illness).",{"count":77,"type":22},582,[25],"To compare the neurological recovery and complication rate of autogenous cranioplasty(CP) within 6 weeks after decompressive craniectomy (DC) with that of autogenous cranioplasty within 3\\~6 months after DC.",[81],"Cranial Defect",[83,84,85,86],"Decompressive craniectomy and Cranioplasty","operation opportunity","ultra-early","Autologous skull","2025-09-17",{"date":89,"type":36},"2025-09-19",{"date":91,"type":22},"2025-10-01",{"date":93,"type":22},"2027-09-01",{"name":42,"class":43},7,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100541420","treatment-of-vasospasm-of-aneurysmal-subarachnoid-hemorrhage-with-intrathecal-nicardipine---fast-it-trial-100541420","NCT06329635","Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial","Trial of Treatment of Vasospasm Associated With Aneurysmal Subarachnoid Hemorrhage With Intrathecal Injection of Nicardipine: a Multi-center, Prospective, Double-blinded, Randomized Controlled Trial","Inclusion criteria:\n\n1. Age 18-80.\n2. Spontaneous SAH confirmed by head CT.\n3. Saccular brain aneurysm is identified and treated, either surgically or endovascularly.\n4. SAH Fisher grade \\>1 or modified Fisher grade \\>0.\n5. EVD placed for acute hydrocephalus, or LD placed for draining bloody CSF as deemed necessary by the treating physician.\n6. Any clinical scenario leading to the diagnosis of possible vasospasm, which includes:\n\n   1. Mean flow velocity of MCA \\>120, or Lindegaard Ratio ( LR ) \\> 3.\n   2. Any intracranial artery including MCA, ACA, PCA, and BA, TCD showed an upward trend of mean flow velocity for 2 consecutive days (\\>25cm\u002Fs\u002Fday).\n   3. Clinical deterioration including mental status change (GCS score decrease \\> 2) and focal neurological deficit unable to be attributed to other known neurological reasons.\n   4. Evidence of vasospasm on CTA or DSA, or ischemic change by CTP, MRI.\n7. Within 14 days of onset of SAH.\n8. Informed consent obtained from the patient or family member.\n\nExclusion criteria:\n\n1. Hunt-Hess Grade 5 or WFNS Grade 5 (no clinical improvement after EVD placement for acute hydrocephalus).\n2. Bacterial or distal aneurysms without subarachnoid hemorrhage in the basal cisterns.\n3. The treating physician determines that the culprit aneurysm has not been fully repaired, with a very high likelihood of rebleeding in the near term.\n4. History of head trauma within the past 3 months.\n5. Any recent brain disease within 3 months, such as tumors, stroke, epilepsy, vasculitis, arteriovenous malformation, hydrocephalus, etc.\n6. History of psychiatric disorders or seizures within 3 months.\n7. Severe concurrent medical conditions.\n8. Pregnant women or those of childbearing potential with a positive urine or serum β-human chorionic gonadotropin (HCG) test.\n9. Lactating women.\n10. Life expectancy of less than 1 year prior to aSAH onset.\n11. Pre-morbid mRS score \\>1.\n12. Participation in another randomized clinical trial that may confound the evaluation of this study.",{"count":104,"type":22},396,[25],"To investigate whether patients with cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage have a better prognosis with intrathecal nicardipine injection via extraventricular drainage or lumbar drainage.",[108,109],"Aneurysmal Subarachnoid Hemorrhage","Vasospasm",[108,109,111,112,113],"Delayed cerebral ischemia","Nicardipine","Intrathecal injection","2025-09-02",{"date":116,"type":36},"2025-09-08",{"date":118,"type":36},"2024-05-27",{"date":120,"type":22},"2026-05",{"name":42,"class":43},28,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":130,"targetDuration":132,"studyType":54,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100600641","research-on-the-clinical-value-of-cranial-ct-and-cta-for-cerebral-hemorrhage-patients-100600641","NCT07100132","Research on the Clinical Value of Cranial CT and CTA for Cerebral Hemorrhage Patients","Research on the Clinical Value of Cranial CT and CTA in Patients With Cerebral Hemorrhage","Inclusion Criteria:\n\n(1) Patients who were confirmed to have cerebral hemorrhage through head CT imaging examination upon admission; (2) Those who completed head CT and CTA within 8 hours of onset and had a follow-up CT within 24 hours of admission; (3) With complete clinical data.\n\nExclusion Criteria:\n\n(1) Patients who cannot complete CT and CTA within the prescribed time; (2) Patients with secondary cerebral hemorrhage due to cerebral vascular malformations, brain tumors, brain trauma, cerebral aneurysms, etc.; (3) Patients who have been taking oral anticoagulants for a long time or have blood system diseases; (4) Primary intraventricular hemorrhage.",{"count":131,"type":22},300,"6 Months","The objective of this observational study is to investigate the predictive value of various imaging signs in patients with intracerebral hemorrhage, thereby providing a reference for clinical diagnosis and treatment. The primary aim is to evaluate the association between specific imaging signs and both hematoma expansion and poor outcomes in these patients.",[135],"Intracerebral Hemorrhage (ICH)","2025-07-27",{"date":138,"type":36},"2025-08-03",{"date":91,"type":22},{"date":141,"type":22},"2027-06-01",{"name":42,"class":43},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":152,"conditions":153,"keywords":159,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":67},"100548920","machine-learning-based-longitudinal-study-of-post-icu-syndrome-development-trajectory-in-critically-ill-patients-and-construction-of-clinical-early-warning-models-a-research-protocol-for-longitudinal-study-100548920","NCT06427265","Machine Learning-based Longitudinal Study of Post-ICU Syndrome Development Trajectory in Critically Ill Patients and Construction of Clinical Early Warning Models: a Research Protocol for Longitudinal Study","Inclusion Criteria patients :\n\n* Length of stay in ICU ≥24h;\n* Age ≥18 years old;\n* Conscious when leaving ICU, communicating with investigators without barriers;\n* Informed consent. Family members：\n* One family member ≥18 years of age was selected for each patient;\n* Assume the main role of caring for patients and medical decision-making;\n* No history of mental illness or other serious organic diseases;\n* Informed consent and voluntary participation in this study.\n\nExclusion Criteria patients :\n\n* Have been in ICU for more than 24h within 3 months before this admission;\n* Transferred to another ICU;\n* Cognitive impairment existed before ICU admission (BDRS \\> 4 points);\n* Severe hearing impairment, dysarthria, etc., which cannot be followed up;\n* Unable to complete the questionnaire survey due to serious illness.\n\nFamily members:\n\n* Family members refuse to participate in the study due to their own reasons;\n* Severe hearing and language impairment, unable to cooperate with researchers.","100 Years",{"count":151,"type":22},840,"This project intends to track and evaluate whether post-ICU syndrome will occur 7 days, 1 month, 3 months and 6 months after ICU patients are transferred out of the ICU through a longitudinal study, apply the latent category growth model to identify different trajectory patterns of post-ICU syndrome in critically ill patients, and use modern machine learning models to build an early warning model of the trajectory patterns of post-ICU syndrome.",[154,155,156,157,158],"Intensive Care Unit Syndrome","Prediction","Cognitive Impairment","Sleep Disorder","Memory Disorders",[160,161,162],"Post-icu syndrome","Prediction model","Development Trajectory","2025-05-26",{"date":165,"type":36},"2025-05-31",{"date":167,"type":36},"2023-12-01",{"date":169,"type":22},"2026-06-01",{"name":42,"class":43},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":67},"100554278","early-phase-1-an-exploratory-study-of-individualized-neo-antigen-mrna-cancer-vaccine-innopcv-in-advanced-solid-tumor-treatment-100554278","NCT06497010","An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor Treatment","An Open Label, Prospective, Exploratory Study to Assess the Safety and Efficacy of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Combination With PD-1 in Participants With Advanced Solid Tumor","Inclusion Criteria:\n\n* 18-75 years, male or female.\n* Histologically\u002Fcytologically or clinically confirmed advanced unresectable protocol-specified solid malignancies.\n* Participants with Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.\n* Life expectation \\>= 12weeks.\n* Participants must have a formalin-fixed paraffin-embedded (FFPE) tumor sample available (for example, from their prior surgery) that is suitable for the next-generation sequencing (NGS) required for this study.\n* Adequate organ function.\n* Participants must agree to use adequate contraception from the first dose of study medication through 180 days after the last dose of study medication (male and female participants of childbearing potential).\n\nExclusion Criteria:\n\n* Not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better from the adverse events (except for alopecia, vitiligo, neurotoxicity, hypothyroidism hormone replacement therapy) caused by therapy administered within 4 weeks before the first dose of PD-1.\n* Participants with a history of (non-study tumor) malignancy (except for skin squamous cell carcinoma and basal cell carcinoma, in situ cervical or breast carcinoma) within 3 years before the first dose of PD-1.\n* Participation in a study of an investigational agent or using an investigational device within 30 days before the first dose of PD-1.\n* Previously received any adoptive cell therapy (including but not limited to tumor-infiltrating lymphocyte TILs, chimeric antigen receptor T cells (CAR-T) and T cell receptor chimeric T cells (TCR-T)), therapeutic tumor vaccines, etc.\n* Participants received chemotherapy, radiotherapy (palliative radiotherapy is allowed), and immune activator (including but not limited to IL-2) and other antitumor therapy within 21 days before the first dose; Participants received Chinese herbal medicine within 2 weeks before the first dose of PD-1.\n* Major surgery (excluding diagnostic biopsy) or significant trauma had not been fully recovered within 28 days before the first dose of PD-1.\n* Participants received live attenuated vaccine within 28 days before starting study treatment or planned to receive live attenuated vaccine during the study and within 60 days after ending the study drug treatment.\n* Active autoimmune disease or a documented history of autoimmune disease or the syndrome that requires systemic steroids or immunosuppressive agents, except vitiligo or resolved childhood asthma\u002Fatopy.\n* Positive for Human Immunodeficiency Virus (HIV), Hepatitis B (HBV-DNA≥ 500IU\u002Fml), or Hepatitis C virus (Hepatitis C Virus Ribonucleic Acid \\[HCV RNA\\] (qualitative) is detected).\n* Previously identified hypersensitivity to components of the formulations used in this study.","75 Years",{"count":180,"type":22},40,[182],"EARLY_PHASE1","This is an open-label, prospective, exploratory clinical study, which is divided into two phases: dose escalation phase (Phase Ia) and expansion phase (Phase Ib). After completing the dose-escalation phase (Stage Ia) (5-11 patients), the investigator will select the dose group (RP2D) based on safety, tolerability, and preliminary immune-related characteristics and efficacy data, and choose 2-3 advanced solid tumors to enter the expansion phase (Stage Ib).",[185],"Advanced Solid Tumor","2025-04-29",{"date":188,"type":36},"2025-05-01",{"date":190,"type":36},"2024-08-29",{"date":192,"type":22},"2026-12",{"name":42,"class":43},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":67},"100580116","phase-4-interleukin-17-il-17-inhibitor-in-combination-with-tumor-necrosis-factor--tnf-inhibitor-for-the-treatment-of-ankylosing-spondylitis-100580116","NCT06833112","Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis","Efficacy and Safety of Interleukin-17 Inhibitor in Combination With Tumor Necrosis Factor α Inhibitor in the Treatment of Ankylosing Spondylitis","Inclusion Criteria:\n\n1. Male or female at least 18 years old;\n2. diagnosed with AS according to the 1984 New York Modified Criteria;\n3. Poor response after at least 2 NSAIDs (cumulative treatment ≥ 4 weeks), or contraindication or intolerance to NSAIDs therapy;\n4. BASDAI score of ≥ 4 and total back pain VAS score of ≥ 4 at baseline;\n5. Subjects who need to take NSAIDs (including COX-1 or COX-2 inhibitors) as established treatment for AS, and the NSAIDs should be on a stable dose for at least 2 weeks (inclusive) before screening and the dose is expected to be stable during the study;\n6. Voluntary treatment with adalimumab and secukinumab;\n7. Appropriate contraceptive measures for women of childbearing age;\n8. without other rheumatic diseases.\n9. Able to understand study requirements, provide written informed consent, and comply with trial protocol procedures (including required visits)\n\nExclusion Criteria:\n\n1. With unstable vital signs, coma, mental and cognitive impairment;\n2. Patients with severe systemic diseases and other serious chronic diseases;\n3. Pregnant or lactating patients;\n4. History of malignant tumor in the past 5 years;\n5. Positive test for the following infection markers: human immunodeficiency virus (HIV), hepatitis B, hepatitis C, syphilis antibody;\n6. Patients with active or recurrent history of infection; With active tuberculosis or have a history of active tuberculosis in the past;\n7. Moderate to severe heart failure (New York Heart Association grade 3-4);\n8. Allergic to any of the components of adalimumab (HS016) or secukinumab;\n9. Subjects who are participating in clinical research of other drugs;\n10. In addition to the above, the investigator judged that there are other reasons that are not suitable for participating in this clinical study.",{"count":202,"type":22},10,[204],"PHASE4","The aim of the study is to investigate the efficacy and safety of adalimumab in combination with secukinumab for the treatment of ankylosing spondylitis.",[207],"Ankylosing Spondylitis",[209,210,211],"ankylosing spondylitis","Secukinumab","adalimumab","2025-02-15",{"date":214,"type":36},"2025-02-18",{"date":216,"type":22},"2025-02",{"date":218,"type":22},"2028-02",{"name":42,"class":43},""]